The relevance of CPP, when it is required, and how PLG can support

The relevance of CPP, when it is required, and how PLG can support

The CPP, issued in the format recommended by the World Health Organization (WHO), is a document internationally recognized by national drug regulatory authorities for establishing the status of a pharmaceutical product under a national drug product licensing system.

The certificate aims to accelerate the availability of new medicines, predominantly in countries that cannot complete full quality, safety, and efficacy. It summarizes essential data, reducing the time to market products by relying on a prior health authority review and eliminating redundant evaluations.

PLG offers the following CPP services to clients

PLG offers the following CPP services to clients

  • Regulatory advice in applying for a CPP
  • Preparation and submission of CPP on behalf of the client from any EU country requested for any importing country
  • Legalization of CPP from the corresponding importing country’s embassy
  • Notarization of CPP from the corresponding health authority

Leveraging PLG’s global capacity adds value for clients

Leveraging PLG’s global capacity adds value for clients

CPP provision involves the coordination among key stakeholders, the client, the health authority, and third parties for notarization and legalization (a common requirement). We manage the entire process and stakeholders, alleviating our clients’ burden.

Additionally, we can leverage our experience and network with the health authorities to expedite timelines.

KEY FIGURES :

50

CPPs obtained on behalf of clients within the past three years.

10-14

Average number of days from the date of application submission to receive a signed and notarized CPP.

30+

Importing countries are supported globally, including Argentina, Austria, Australia, Brazil, Canada, Switzerland, France, Israel, Saudi Arabia, Egypt, Jordan, and the UK.